|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400090714 |
|
最近更新日期: Date of Last Refreshed on: |
2024-10-12 09:35:27 |
|
注册时间: Date of Registration: |
2024-10-12 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
关于运动功能障碍辅助评估软件对运动功能评估的有效性和安全性的前瞻性、多中心、 两阶段、开放、对照的临床研究 |
|
Public title: |
Validity and Safety of Analysing Movement Functions Using the Movement Dysfunction Assessment Software (MoDAS): a Prospective, Multicenter, Two-Phase, Open, Controlled Clinical Study. |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
关于运动功能障碍辅助评估软件对运动功能评估的有效性和安全性的前瞻性、多中心、 两阶段、开放、对照的临床研究 |
|
Scientific title: |
Validity and Safety of Analysing Movement Functions Using the Movement Dysfunction Assessment Software (MoDAS): a Prospective, Multicenter, Two-Phase, Open, Controlled Clinical Study. |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王宝 |
研究负责人: |
于生元 |
|
Applicant: |
bao Wang |
Study leader: |
shengyuan Yu |
|
申请注册联系人电话: Applicant telephone: |
+86 189 8511 9176 |
研究负责人电话: Study leader's telephone: |
+86 135 0117 1068 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
624333788@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
yusy1963@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区复兴路28号 |
研究负责人通讯地址: |
北京市海淀区复兴路28号 |
|
Applicant address: |
28 Fuxing Road, Haidian District, Beijing |
Study leader's address: |
28 Fuxing Road, Haidian District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中国人民解放军总医院第一医学中心 |
||
|
Applicant's institution: |
Chinese PLA General Hospital First Medical Center |
||
|
研究负责人所在单位: |
中国人民解放军总医院第一医学中心 |
||
|
Affiliation of the Leader: |
Chinese PLA General Hospital First Medical Center |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
S2023-693-03; S2023-693-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee Of Chinese PLA General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-12-28 00:00:00 |
||
|
伦理委员会联系人: |
曹老师 |
||
|
Contact Name of the ethic committee: |
Teacher Cao |
||
|
伦理委员会联系地址: |
北京市海淀区复兴路28号 |
||
|
Contact Address of the ethic committee: |
28 Fuxing Road, Haidian District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6693 7166 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
301irb@sina.com |
|
研究实施负责(组长)单位: |
中国人民解放军总医院第一医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
Chinese PLA General Hospital First Medical Center |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区复兴路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
28 Fuxing Road, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self raised |
||||||||||||||||||||||
|
Target disease: |
Parkinson's diesease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
主要目的 :本研究通过分析观察组、对照组在潜在和存在全身或部分僵直、颤抖,运动的速度、幅度异常,以及姿态、步态改变等运动功能障碍及帕金森综合征表现的运动功能障碍评估中的主要运动特征参数差异情况,来评估软件在临床应用中的有效性。 次要目的 :通过探索性运动特征参数差异情况、软件易用性评分来评估软件在临床应用中的有效性和软件的功能是否满足临床需求。 以软件故障发生率、不良事件及严重不良事件发生率为安全性评价指标,评估软件在临床使用中的安全性。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary objectives: This study uses differences in movement parameters as the primary validity endpoints. The MoDAS software will analyse movement test videos and generate movement parameter results, while in a control group human physicians will provide their assessment results based on original test videos and visualized parameter data charts. Secondary objectives: Secondary validity endpoints include differences in exploratory movement parameters and software usability ratings. Safety endpoints in this study are defined as the software malfunction rate and the frequencies of adverse events (AEs) and serious adverse events (SAEs). |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1) 年龄 40 周岁至 80 周岁,性别不限; 2) 经临床诊断为潜在和存在全身或部分僵直、颤抖,运动的速度、幅度异常,以及姿态、步态改变等运动功能障碍及帕金森综合征表现的患者; 3) 患者本人和/或其法定监护人同意参加本临床研究并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Men or women aged between 40 and 80 years. 2.Patients diagnosed clinically with potential or existing systemic or partial stiffness, tremors, abnormal speed and amplitude of movement, as well as changes in posture, gait, and other motor dysfunction and Parkinson's syndrome manifestations; 3.The patient and/or their legal guardian agree to participate in this clinical study and sign an informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1) 经研究者判断认知功能受限、神志不清晰或精神状态不稳定不适合参与本研究的患者; 2) 有严重的心、肺、肝、肾功能不全,有严重贫血或其余的基础疾病以致于活动能力受限不能参与本研究的患者; 3) 生命体征不稳定,有活动性感染,或者目前有其余系统的疾病需优先治疗的患者; 4) 研究者认为其它不适宜参加本次临床研究的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.The patient is cognitive impaired, delirious or not mentally stable enough to participate in the study. 2.The patient has underlying conditions that might bring undesirable consequences after taking movement tests in study, including but not limited to severe functional impairment of the heart, lung, liver or kidney as well as severe anemia. 3.The patient has unstable vital signs, active infections or other systemic dieases that require immediate treatment. 4.The patient is deemed unfit for this study by the investigator. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-05-01 00:00:00至 To 2025-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2024-10-21 00:00:00 至 To 2025-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不适用 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |